Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome.
Janssen JJWM, Löwenberg B, Manz M, Biemond BJ, Westerweel PE, Klein SK, Fehr M, Sinnige HAM, Efthymiou A, Legdeur MCJC, Pabst T, Gregor M, van der Poel MWM, Deeren D, Tick LW, Jongen-Lavrencic M, van Obbergh F, Boersma RS, de Weerdt O, Chalandon Y, Heim D, Spertini O, van Sluis G, Graux C, Stüssi G, van Norden Y, Ossenkoppele GJ. Janssen JJWM, et al. Among authors: van sluis g. Leukemia. 2022 Sep;36(9):2189-2195. doi: 10.1038/s41375-022-01657-3. Epub 2022 Jul 22. Leukemia. 2022. PMID: 35869267 Clinical Trial.
Clofarabine added to intensive treatment in adult patients with newly diagnosed ALL: the HOVON-100 trial.
Rijneveld AW, van der Holt B, de Weerdt O, Biemond BJ, van de Loosdrecht AA, van der Wagen LE, Bellido M, van Gelder M, van der Velden WJFM, Selleslag D, van Lammeren-Venema D, Halkes CJM, Fijnheer R, Havelange V, van Sluis GL, Legdeur MC, Deeren D, Gadisseur A, Sinnige HAM, Breems DA, Jaspers A, Legrand O, Terpstra WE, Boersma RS, Mazure D, Triffet A, Tick LW, Beel K, Maertens JA, Beverloo HB, Bakkus M, Homburg CHE, de Haas V, van der Velden VHJ, Cornelissen JJ; Dutch-Belgian HOVON Cooperative group. Rijneveld AW, et al. Among authors: van sluis gl. Blood Adv. 2022 Feb 22;6(4):1115-1125. doi: 10.1182/bloodadvances.2021005624. Blood Adv. 2022. PMID: 34883506 Free PMC article. Clinical Trial.
Treatment patterns and clinical outcomes of asciminib in a real-world multiresistant chronic myeloid leukemia patient population.
Kockerols CCB, Janssen JJWM, Blijlevens NMA, Klein SK, Van Hussen-Daenen LGM, Van Gorkom GGY, Smit WM, Van Balen P, Biemond BJ, Cruijsen MJ, Corsten MF, Te Boekhorst PAW, Koene HR, Van Sluis GL, Cornelissen JJ, Westerweel PE. Kockerols CCB, et al. Among authors: van sluis gl. Haematologica. 2023 Jan 1;108(1):240-244. doi: 10.3324/haematol.2022.281386. Haematologica. 2023. PMID: 36073515 Free PMC article. No abstract available.
Long-term thrombin inhibition promotes cancer cell extravasation in a mouse model of experimental metastasis.
Niers TM, Brüggemann LW, VAN Sluis GL, Liu RD, Versteeg HH, Büller HR, VAN Noorden CJ, Reitsma PH, Spek CA, Richel DJ. Niers TM, et al. Among authors: van sluis gl, van noorden cj. J Thromb Haemost. 2009 Sep;7(9):1595-7. doi: 10.1111/j.1538-7836.2009.03529.x. Epub 2009 Jun 24. J Thromb Haemost. 2009. PMID: 19558435 Free article. No abstract available.
Cancer and thrombosis: from molecular mechanisms to clinical presentations.
Buller HR, van Doormaal FF, van Sluis GL, Kamphuisen PW. Buller HR, et al. Among authors: van doormaal ff, van sluis gl. J Thromb Haemost. 2007 Jul;5 Suppl 1:246-54. doi: 10.1111/j.1538-7836.2007.02497.x. J Thromb Haemost. 2007. PMID: 17635733 Free article. Review.
13 results